Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes

OBJECTS: Imigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function in Chinese patients with type-2 diabetes mellitus (T2DM). METHODS: A total of 37 Chinese T2DM patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xu, Liu, Yang, Liu, Hongzhong, Li, Haiyan, Yang, Jianhong, Hu, Pei, Xiao, Xinhua, Liu, Dongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488395/
https://www.ncbi.nlm.nih.gov/pubmed/34616361
http://dx.doi.org/10.3389/fendo.2021.694390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488395/
https://www.ncbi.nlm.nih.gov/pubmed/34616361
http://dx.doi.org/10.3389/fendo.2021.694390

Ejemplares similares